4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Dermatomyositis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 155 ongoing clinical trials involving Dermatomyositis
Of the 155 trials,55 trials are in Phase III
Furthermore, 43 trials are in Phase II/III

Number of ongoing Clinical Trials (for drugs) involving Dermatomyositis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Dermatomyositis, a Musculoskeletal Disorders. The largest number of ongoing clinical trials for Dermatomyositis is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in Dermatomyositis-related drug trials.

Kezar Life Sciences Inc: The leading ongoing Dermatomyositis related clinical trials sponsor

Kezar Life Sciences Inc is the top sponsor for Dermatomyositis-related ongoing clinical trials.

Hamamatsu University School of Medicine, Local Health Reggio Emilia, Alexion Pharmaceuticals Inc, and Bristol-Myers Squibb Co are a few other notable clinical trial sponsors involving Dermatomyositis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Dermatomyositis

Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar), Methylprednisolone, and Human normal immunoglobulin (Octagam, Gamten, NewGam, Globiga, and Panzyga) are among the key marketed drugs involving Dermatomyositis.

Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) is a purified preparation of the adrenocorticotropic hormone (ACTH) obtained from porcine pituitary. It functions via Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Agonist; Melanocortin Receptor 3 (MC3R) Agonist; Melanocortin Receptor 4 (MC4R) Agonist; Melanocortin Receptor 5 (MC 2 or MC5R) Agonist; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Agonistmechanism of action. It is formulated as injection gel for intramuscular and subcutaneous route of administration and powder for solution for intravenous, intramuscular and subcutaneous routes of administration. Corticotropinwas first approved in 1950 and is marketed globally in US and New Zealand by several prominent pharma giants including Mallinckrodt LLC.

Methylprednisoloneis a glucocorticoid, anti-inflammatory agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonistmechanism of action.  It is formulated as tablets for oral administration, lyophilized powder for solution, suspension and solution for intravenous, intramuscular, intraarticular, intralesional, intrasynovial route of administration. It is also formulated as enema for rectal administration and as ointment for topical administration.Methylprednisolonewas first approved in 1957 and is marketed globally including the US, the UK, France, Germany, and Japan by several prominent pharma giants including Pfizer Inc.